Kymera Therapeutics, Inc.
KYMR
$25.97
$0.953.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -392.43% | -18.20% | -8.41% | -18.64% | 58.79% |
| Total Depreciation and Amortization | 123.01% | 122.01% | 115.33% | 66.21% | 8.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.38% | 8.08% | 5.71% | 71.50% | 20.30% |
| Change in Net Operating Assets | -129.86% | -109.82% | -84.44% | 47.27% | 188.14% |
| Cash from Operations | -867.98% | -58.59% | -21.78% | 9.95% | 120.35% |
| Capital Expenditure | 91.95% | 102.34% | 56.45% | -84.63% | -3,016.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 127.31% | -330.17% | -56.38% | -1,230.36% | 162.03% |
| Cash from Investing | 261.80% | -360.58% | -56.35% | -1,444.81% | 138.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -131.68% | -88.53% | -5.39% | 11.31% | 403.28% |
| Issuance of Common Stock | 3,014.07% | 187,630.60% | 7.63% | 23,725.44% | -55.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 42.97% | 121,904.85% | 8.20% | 30,422.52% | -0.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -66.99% | 50.21% | -1,470.87% | 9.78% | 133.16% |